A Study of Plasma Myeloperoxidase Levels in Chronic Heart Failure: Prognostic Significance and Echocardiographic Factors

Abstract

Background: An important biomarker for chronic heart failure is raised plasma myeloperoxidase (MPO) concentrations, which indicate increased oxidative stress and leukocyte activation. When managing this intricate cardiovascular condition, monitoring MPO levels provides information for prognosis and customized therapies. Aims and Objective: To study Plasma myeloperoxidase levels in chronic heart failure and its prognostic significance and Echocardiographic factors. Methodology: The ADEPT study's neurohormonal sub-study, which focuses on 140 ambulatory patients with stable, chronic systolic heart failure, is described in depth in the research methodology. The study uses SAS and JMP statistical software versions 5.1 and 9.1 for statistical analyses, and it covers participant demographics, data collection techniques, laboratory protocols, and statistical analysis. When a p-value was 0.05 or less, it was considered significant. Result: “Elevated plasma myeloperoxidase (MPO) in chronic heart failure (CHF) is linked to right ventricular
dysfunction and influences the efficacy of cardiac resynchronization therapy. Higher MPO levels correlate with increased risk of adverse events, and integrating MPO with B-type natriuretic peptide enhances the accuracy of predicting future clinical outcomes, offering a
valuable tool for personalized CHF management. Conclusion: “Elevated myeloperoxidase (MPO) levels in chronic heart failure (CHF) correlate with worsened right ventricular function, especially in patients with LVEF below 35%. High MPO levels predict adverse outcomes; enhancing BNP, testing is accuracy, and serve as a potential prognostic indicator for CRT response. MPO also reflects CHF severity in echocardiographic parameters, underlining its significance in predicting adverse clinical events.